Pharmalink Enters Manufacturing Agreement for Busulipo™

Pharmalink Enters Manufacturing Agreement for Busulipo™ PR Newswire STOCKHOLM, Sweden, November 12, 2012 STOCKHOLM, Sweden, November 12, 2012 /PRNewswire/ -- Pharmalink AB, a Swedish specialty pharma company, today announces it has entered into a service contract with GP Pharm for the manufacturing of Pharmalink's Busulipo™, which is under development to provide a best-in-class conditioning agent for use prior to hematopoietic stem cell transplantation (HSCT), often known as bone marrow transplantation. GP Pharm is a Spanish biopharmaceutical company that focuses on injectable oncology products. Besides its proprietary products it also offers services in contract development and contract manufacturing. The agreement covers the manufacturing of Busulipo from clinical to commercial quantities and is an important step in progressing the product towards the market. No commercial terms were disclosed. Johan Häggblad, Managing Director of Pharmalink, said: "Busulipo is an immediate release liposome formulation that improves the safety and stability of the chemotherapy agent busulfan that is currently the gold standard for use in conditioning prior to HSCT. Busulipo allows the elimination of the toxic solvent DMA and has been designed to have a two year shelf life and increased stability after reconstitution. GP Pharm has an excellent track record in the manufacturing of complex injectables and specifically with liposomes.